Trial Profile
Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Berzosertib (Primary)
- Indications Brain metastases; Neuroendocrine tumours; Non-small cell lung cancer; Small cell lung cancer
- Focus Adverse reactions
- 29 Sep 2023 Planned End Date changed from 24 Feb 2024 to 22 Sep 2024.
- 25 Feb 2023 Planned End Date changed from 30 Dec 2023 to 24 Feb 2024.
- 03 Jan 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2023.